Cost Effectiveness of Platelets Treated with Pathogen Reduction Compared to Secondary Testing In March of 2016 the FDA introduced draft guidelines recommending additional precautions to prevent bacterial contamination in platelets. Since both… October 4, 2017
Frequent Donors Give More Blood but Are More Likely to be Iron Deficient The first randomized trial assessing donation-intervals recently published in The Lancet will help to clarify safe whole blood donation frequencies… September 27, 2017
Patients with Moderate ADAMTS13 Deficiency have Increased Risk of Dying Thrombotic microangiopathies (TMAs) may develop from diverse group of etiologies. While activity levels less than 10% of ADAMTS13 help to… September 21, 2017
Low Hematocrit and Bleeding Risk for Patients with Hypoproliferative Thrombocytopenia Prophylactic platelet transfusions are the standard of care for hypoproliferative thrombocytopenia. Over one thousand adult patients (n=1077) enrolled in a… September 13, 2017
FDA Approves CAR-T Gene Therapy for Acute Lymphoblastic Leukemia With the FDA approval of the first gene therapy, or a nucleic acid drug, we have entered a new era… September 7, 2017
Leukoreduction of Platelet Units Followed by Mirasol Pathogen Reduction May Prevent Alloimmunization Alloimmunization to donor platelets is common in transfused, immunosuppressed oncology patients. Leukoreduction reduces alloimmunization by more than half. Researchers recently… August 30, 2017
Intravenous Immunoglobulin Treatment for Patients with Heparin-Induced Thrombocytopenia Patients Unresponsive to Standard Treatment Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment with significant risks of morbidity and mortality. HIT is caused… August 23, 2017
Bedside Checklists Could Prevent Most ABO-Incompatible Transfusions and Other Adverse Events Since 1996, the hemovigilance surveillance system in the United Kingdom has collected and published yearly reports on the serious hazards… August 16, 2017
Negligible Risk of Transfusion-Transmitted Creutzfeldt Jakob Disease Creutzfeldt Jakob Disease (CJD) is a fatal and rapidly progressing neurodegenerative disorder caused by misfolded proteins, or prions, in the… August 10, 2017
Low ADAMTS13 antigen and high ADAMTS13 antibody levels associated with mortality in TTP patients While thrombotic thrombocytopenic purpura (TTP) has a mortality rate of approximately 10% even when treated, predictors of mortality are unknown. … August 1, 2017
